Combinational Diuretics in Heart Failure.

Acetazolamide Diuretics Furosemide Heart failure Spironolactone Thiazides

Journal

Current heart failure reports
ISSN: 1546-9549
Titre abrégé: Curr Heart Fail Rep
Pays: United States
ID NLM: 101196487

Informations de publication

Date de publication:
09 Apr 2024
Historique:
accepted: 20 03 2024
medline: 9 4 2024
pubmed: 9 4 2024
entrez: 8 4 2024
Statut: aheadofprint

Résumé

Diuretics are the cornerstone therapy for acute heart failure (HF) and congestion. Patients chronically exposed to loop diuretics may develop diuretic resistance as a consequence of nephron remodelling, and the combination of diuretics will be necessary to improve diuretic response and achieve decongestion. This review integrates data from recent research and offers a practical approach to current pharmacologic therapies to manage congestion in HF with a focus on combinational therapy. Until recently, combined diuretic treatment was based on observational studies and expert opinion. Recent evidence from clinical trials has shown that combined diuretic treatment can be started earlier without escalating the doses of loop diuretics with an adequate safety profile. Diuretic combination is a promising strategy for overcoming diuretic resistance in HF. Further studies aiming to get more insights into the pathophysiology of diuretic resistance and large clinical trials confirming the safety and efficacy over standard diuretics regimens are warranted.

Identifiants

pubmed: 38589570
doi: 10.1007/s11897-024-00659-9
pii: 10.1007/s11897-024-00659-9
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Joan Carles Trullàs (JC)

Internal Medicine Department, Hospital d'Olot I Comarcal de La Garrotxa, Avinguda Dels Països Catalans 86, 17800, Olot, Girona, Spain. jctv5153@comg.cat.
Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca I Innovació en Ciències de La Vida I de La Salut a La Catalunya Central (IrisCC), Ctra. de Roda, 70 08500 Vic, Barcelona, Spain. jctv5153@comg.cat.

Jesús Casado (J)

Internal Medicine Department, Hospital Universitario de Getafe, Carretera de Madrid - Toledo, Km 12,500, 28905, Madrid, Spain.

Marta Cobo-Marcos (M)

Cardiology Department, Hospital Universitario Puerta de Hierro Majadahonda (IDIPHISA), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Francesc Formiga (F)

Internal Medicine Department, Hospital Universitari de Bellvitge, IDIBELL, Carrer de La Feixa Llarga S/N, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.

José Luís Morales-Rull (JL)

Internal Medicine Department, Heart Failure Unit, Hospital Universitari Arnau de Villanova, Institut de Recerca Biomédica (IRBLleida), Avinguda Alcalde Rovira Roure, 80, 25198, Lleida, Spain.

Julio Núñez (J)

Cardiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain.
Department of Medicine, University of Valencia, Valencia, Spain.
Centro de Investigación Biomédica en Red - Cardiovascular (CIBER-CV), Madrid, Spain.

Luís Manzano (L)

Internal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, M-607, 9, 100, 28034, Madrid, Spain.

Classifications MeSH